Tamoxifen may increase insulin requirement in breast cancer patients with type 1 diabetes mellitus through its agonistic activity on splenic endothelial cells and inhibitory effect on pancreatic beta cells.
Mevlut
M
Kurt
Kadri
K
Altundag
Ozden
O
Altundag
Selahattin
S
Turen
D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy*; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D013154:Spleen / Q000166:cytology / Q000378:metabolism*; D013629:Tamoxifen / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D007328:Insulin; D013629:Tamoxifen